Vanguard Group
TLOG

Vanguard Group’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Vanguard Group’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-157,349
Closed -$25K – 4128
2016
Q3 		$25K Buy
157,349
+8,700
+6% +$2.01K ﹤0.01% 4064
2016
Q2 		$46K Buy
148,649
+25,974
+21% +$7.22K ﹤0.01% 4084
2016
Q1 		$22K Sell
122,675
-99,325
-45% -$27.6K ﹤0.01% 4121
2015
Q4 		$385K Buy
222,000
+20,800
+10% +$36.6K ﹤0.01% 3893
2015
Q3 		$378K Buy
201,200
+16,100
+9% +$38.3K ﹤0.01% 3923
2015
Q2 		$433K Buy
185,100
+52,785
+40% +$163K ﹤0.01% 3904
2015
Q1 		$580K Buy
132,315
+31,616
+31% +$159K ﹤0.01% 3789
2014
Q4 		$485K Buy
100,699
+86,681
+618% +$388K ﹤0.01% 3737
2014
Q3 		$58K Buy
+14,018
New +$65.3K ﹤0.01% 3985

Other funds holding TLOG

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BWA
Burt Wealth Advisors North Bethesda, Maryland $407M AUM 11.98% 1-Year Est. Return

Vanguard Group's TLOG Position: Q4 2016 in Review

Vanguard Group sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2016, closing a stake of 157,349 shares — an estimated $25K sold.

Vanguard Group first reported a position in TLOG in Q3 2014 and held it in 9 quarters. The position peaked at $580K in Q1 2015. 3 funds tracked by Wall St. Rank hold TLOG as of Q4 2016.

  • Vanguard Group reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2016 after selling out during the quarter.
  • Vanguard Group sold 157,349 TetraLogic Pharmaceuticals Corporation shares in Q4 2016, an estimated $25K.
  • Vanguard Group first reported a position in TetraLogic Pharmaceuticals Corporation in Q3 2014 and held it in 9 quarters.
  • Vanguard Group's TetraLogic Pharmaceuticals Corporation position peaked at $580K in Q1 2015.
  • 3 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2016.

Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.